← Eichor
Condition: Lymphatic Diseases Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lymphatic Diseases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04045470Effect of Phlebotomy on Heartrate in Polycythemia Patients
Phase N/A · 1 location(s) · Leiden University Medical Center · NCT05396170Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07043894Activity Levels in Bone Marrow Transplant Patients
Phase N/A · 1 location(s) · Michael Tomasson · NCT04115241Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06874257A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Phase N/A · 6 location(s) · Genetix Biotherapeutics Inc. · NCT06271512Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07078500Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06232694Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia
Phase N/A · 1 location(s) · Institute of Mother and Child, Warsaw, Poland · NCT06984445Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06754267Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07494565Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy
Phase N/A · 3 location(s) · Centre Hospitalier Universitaire, Amiens · NCT03450512Zanubrutinib Combined With G-CVP in Previously Untreated FL
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06959732Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07235501Effects of Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD) on Memory and Cognitive Function in Adults
NA · 1 location(s) · Tao Liu · NCT07084701A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considerin
NA · 1 location(s) · Columbia University · NCT05963971A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A
Phase 2 · 19 location(s) · Shanghai Tong Ren Hospital · NCT05736965Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Phase N/A · 1 location(s) · Duke University · NCT01745237Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Phase 2 · 1 location(s) · New York Medical College · NCT07013565A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymph
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04484012Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Phase 1 · 5 location(s) · Chongqing Peg-Bio Biopharm Co., Ltd. · NCT06880081A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomi
Phase 2 · 16 location(s) · Karyopharm Therapeutics Inc · NCT04414475Hematology Biobank: In Vitro Study of Blood Disorders
Phase N/A · 1 location(s) · Albert Einstein College of Medicine · NCT02442011Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Phase 3 · 11 location(s) · Baylor College of Medicine · NCT02670707Development of a Clinical Screening, Diagnostic and Evaluation Tool for Patients With Lower Limb Lymphedema: Aim 4
Phase N/A · 2 location(s) · KU Leuven · NCT06038864
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.